Diagnostic signatures for lung cancer by gut microbiome and urine metabolomics profiling.

Author:

Qiu Bo1,Xi Yu2,Li Ying2,Xie XinQiang2,Liu FangJie1,Wu Lei2,Liang TingTing2,Li Longyan2,Feng Ying2,Guo JinYu3,Wang DaQuan1,Zeng Yu2,Yang Lingshuang2,Zhang Jumei2,Wang Juan2,Chen Moutong2,Xue Liang2,Ding Yu2,Wu QingPing2,Liu Hui1

Affiliation:

1. Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China;

2. Guangdong Provincial Key Laboratory of Microbial Safety and Health, State Key Laboratory of Applied Microbiology Southern China, Guangzhou, China;

3. Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China;

Abstract

e20514 Background: To develop the diagnostic signatures for lung cancer (LC) by gut microbiome and urine metabolomics profiling with multi-omics approach. Methods: We surveyed 145 Fecal Samples and 120 Urine Samples in a cohort containing 109 LC patients and 50 healthy individuals. The total cohort had been separated into testing set and validation set. The testing set comprised 47 patients and 20 healthy individuals (8 first-degree relatives and 12 non-relatives), while the validation set had 48 patients and 30 healthy individuals (14 first-degree relatives and 16 non-relatives). The urine research set comprised 100 patients and 18 first-degree relatives as healthy individuals. Gut microbiota was analyzed through the 16S ribosomal RNA (rRNA) gene sequencing and shotgun metagenomics. Urine untargeted metabolomics was analyzed by liquid chromatography–mass spectrometry (LC–MS) metabolomic analysis. Results: LC patients had a significant shift of intestinal microbiota composition and functional genes distribution compared with healthy individuals. Diagnostic model had been achieved by combining gut microbiome and urine metabolomics profiling, the area under curve (AUC) of the testing set was 0.9997. The model performed reasonably well in the validation set with the AUC of 0.9769. We also found a significant decrease of Prevotella in LA-NSCLC patients and it was negatively correlated with multiple functions in KEGG level 2 in healthy individuals. Conclusions: The current study employs a multi-omics approach, analyses the fecal microbiome and urine metabolites from LC patients and healthy individuals/relatives using a standardized pipeline, and identified disease-associated microbiome shifts across datasets using statistical analysis. We inferred a microbiome-metabolite catalog and its molecular pathway and functional link to host targets, which could be further utilized to aid lung cancer diagnosis and treatment decision.

Funder

None

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3